Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1141 ARTÍCULOS , VIENDO DEL 76 AL 90

The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease

Rohn TT.

Oxid Med Cell Longev. 2013;2013:860959. doi: 10.1155/2013/860959. Epub 2013 Mar 6.

CD4 T cells in immunity and immunotherapy of Alzheimer's disease

Monsonego A, Nemirovsky A, Harpaz I.

Immunology. 2013 Aug;139(4):438-46. doi: 10.1111/imm.12103.

Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies

Rosenmann H.

Curr Alzheimer Res. 2013 Mar;10(3):217-28. doi: 10.2174/1567205011310030001.

Liver X receptors: emerging therapeutic targets for Alzheimer's disease

Sodhi RK, Singh N.

Pharmacol Res. 2013 Jun;72:45-51. doi: 10.1016/j.phrs.2013.03.008. Epub 2013 Mar 28.

Alzheimer disease pharmacologic treatment and treatment research

Schneider LS.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):339-57. doi: 10.1212/01.CON.0000429180.60095.d0.

Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease

Adwan L, Zawia NH.

Pharmacol Ther. 2013 Jul;139(1):41-50. doi: 10.1016/j.pharmthera.2013.03.010. Epub 2013 Apr 3.

Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study

Faxén-Irving G, Freund-Levi Y, Eriksdotter-Jönhagen M, Basun H, Hjorth E, Palmblad J, Vedin I, Cederholm T, Wahlund LO.

J Alzheimers Dis. 2013;36(1):1-6. doi: 10.3233/JAD-121828.

Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease

Martiskainen H, Haapasalo A, Kurkinen KM, Pihlajamäki J, Soininen H, Hiltunen M.

Expert Opin Ther Targets. 2013 Jul;17(7):781-94. doi: 10.1517/14728222.2013.789862. Epub 2013 Apr 11.

Frailty among Alzheimer's disease patients

Koch G, Belli L, Giudice TL, Lorenzo FD, Sancesario GM, Sorge R, Bernardini S, Martorana A.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):507-11. doi: 10.2174/1871527311312040010.

Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

Tayeb HO, Murray ED, Price BH, Tarazi FI.

Expert Opin Biol Ther. 2013 Jul;13(7):1075-84. doi: 10.1517/14712598.2013.789856. Epub 2013 Apr 10.

Why size matters - balancing mitochondrial dynamics in Alzheimer's disease

DuBoff B, Feany M, Götz J.

Trends Neurosci. 2013 Jun;36(6):325-35. doi: 10.1016/j.tins.2013.03.002. Epub 2013 Apr 11.

Effects of SolCos model-based individual reminiscence on older adults with mild to moderate dementia due to Alzheimer disease: a pilot study

Van Bogaert P, Van Grinsven R, Tolson D, Wouters K, Engelborghs S, Van der Mussele S.

J Am Med Dir Assoc. 2013 Jul;14(7):528.e9-13. doi: 10.1016/j.jamda.2013.01.020. Epub 2013 Apr 9.

From soluble aβ to progressive aβ aggregation: could prion-like templated misfolding play a role?

Eisele YS.

Brain Pathol. 2013 May;23(3):333-41. doi: 10.1111/bpa.12049.

The multifunctional anti-inflammatory drugs used in the therapy of Alzheimer's disease

Shi S, Wang Z, Qiao Z.

Curr Med Chem. 2013;20(20):2583-8. doi: 10.2174/0929867311320200006.

Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track?

Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A.

CNS Neurosci Ther. 2013 Aug;19(8):549-55. doi: 10.1111/cns.12095. Epub 2013 Apr 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias